Merrimack Pharmaceutical Inc.

Cambridge, MA, United States

Merrimack Pharmaceutical Inc.

Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Merrimack Pharmaceutical Inc. | Date: 2017-09-06

Provided herein are novel antiErbB3 and anti-IGF-IR antibodies (e.g., monoclonal antibodies). Also provided herein are novel monospecific and bispecific antibodies that are useful as anti neoplastic agents and that bind specifically to human IGF-IR and/or human ErbB3. Exemplary antibodies inhibit signal transduction through both or either of IGF-IR and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-IR binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region.


Patent
Merrimack Pharmaceutical Inc. | Date: 2017-01-11

A liposome-encapsulated formulation of irinotecan can be used for the treatment of pancreatic cancer in combination with 5-fluorouracil and leucovorin, including treatment of patients diagnosed with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine.


Patent
Merrimack Pharmaceutical Inc. | Date: 2017-05-31

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-10-18

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.


Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-10-28

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-11-29

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-11-29

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-11-29

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.


Patent
Merrimack Pharmaceutical Inc. | Date: 2016-11-29

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Loading Merrimack Pharmaceutical Inc. collaborators
Loading Merrimack Pharmaceutical Inc. collaborators